Congress Files Bill Requiring VA to Study Medical Marijuana for PTSD, Pain

Bill Mandates Multi-Year VA Cannabis Research Program

The legislation directs the VA to establish a federally funded, multi-year clinical trial program evaluating cannabis formulations for PTSD and pain within 180 days of enactment. The bill doesn't specify a dollar appropriation but instructs the VA Secretary to allocate "necessary funds" from existing research budgets. Sponsors framed the measure as a response to veteran advocacy groups that have pressed the VA for cannabis access since 2014, when the agency first acknowledged it wouldn't discipline doctors who discuss marijuana with patients in legal states.

The VA currently operates the largest integrated healthcare system in the U.S., serving 9.1 million enrolled veterans annually. Despite state-level legalization in 38 states, federal law has blocked the VA from prescribing or dispensing cannabis. Agency policy prohibits clinicians from completing state medical-marijuana recommendation forms. Veterans who use cannabis in legal states do so outside the VA system, often paying out-of-pocket for products with no clinical oversight.

PTSD and Chronic Pain Endpoints Drive Research Design

The bill specifies two primary endpoints: reduction in PTSD symptom severity as measured by the Clinician-Administered PTSD Scale (CAPS-5), and reduction in opioid use among veterans with chronic pain. Secondary endpoints include sleep quality, suicidal ideation frequency, and quality-of-life metrics. At least 1,000 participants must enroll across multiple medical centers, with recruitment prioritizing combat veterans diagnosed with PTSD between 2001 and 2026.

Study protocols must compare whole-plant cannabis, isolated cannabinoids (THC and CBD), and placebo arms. The bill doesn't mandate specific dosing or delivery methods, leaving those decisions to VA researchers in consultation with the National Institute on Drug Abuse. Results would be due to Congress within four years of the first participant enrollment.

Federal Scheduling Conflict Remains Unresolved

The bill doesn't address cannabis's Schedule I status under the Controlled Substances Act, which classifies it as having no accepted medical use and high abuse potential. That designation has historically limited federally funded research by requiring researchers to obtain cannabis from a single DEA-licensed facility at the University of Mississippi, which produces material that critics say doesn't reflect commercial products available in state markets.

The VA's hands remain tied until Congress or DEA acts on rescheduling—mandating research without fixing the supply chain is procedural theater unless paired with regulatory reform.

The DEA announced in August 2026 that it would consider moving cannabis to Schedule III, which would ease research restrictions but not resolve the VA's prescribing prohibition. That rulemaking isn't expected to conclude before mid-2027. For full background on this story, see the CannIntel topic hub on VA medical marijuana research.

Veteran Advocacy Groups Endorse Bill, Cite Suicide Rates

Iraq and Afghanistan Veterans of America (IAVA) and Veterans of Foreign Wars (VFW) issued joint statements supporting the bill, citing VA data showing 17 veterans die by suicide daily, with PTSD and chronic pain identified as leading risk factors. A 2023 survey by IAVA found 68% of post-9/11 veterans reported using cannabis to manage service-connected conditions, but only 22% disclosed that use to VA providers due to fear of losing benefits or facing disciplinary action.

The American Legion, the nation's largest veterans organization with 1.8 million members, has supported federal cannabis rescheduling since 2019. Its resolution called for removing cannabis from Schedule I and expanding VA research. The Legion hasn't yet commented on the new bill.

Political Pathway Uncertain in Divided Congress

The bill has 12 co-sponsors—seven Democrats and five Republicans—but hasn't been assigned to committee as of October 1. Similar measures introduced in 2022 and 2024 stalled in committee without hearings. Cannabis reform bills face procedural hurdles in both chambers, where leadership has historically declined to schedule floor votes even when bills have majority co-sponsor support.

The House Veterans' Affairs Committee has jurisdiction. Its chairman hasn't commented on the bill. The Senate Veterans' Affairs Committee held a hearing on veteran cannabis access in March 2026 but took no legislative action. Advocates expect the bill to be folded into a broader veterans' health package rather than advance as standalone legislation.

Enforcement and implementation timelines will vary widely depending on DEA rescheduling progress and whether the next Congress prioritizes veterans' health reform. The political variable nobody can model? Whether the VA will comply with a research mandate while cannabis remains Schedule I—or whether the agency will cite the Controlled Substances Act as grounds for delay.